STOCK TITAN

Dynavax Technologies (DVAX) president’s awards paid out in Sanofi deal

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dynavax Technologies President & COO David F. Novack reported automatic changes to his equity awards tied to the acquisition of Dynavax by Sanofi. Under a Merger Agreement, Sanofi’s subsidiary completed a tender offer for all Dynavax common shares at $15.50 per share in cash, then merged into Dynavax on February 10, 2026, leaving Dynavax as an indirect wholly owned subsidiary.

At the merger’s effective time, each Dynavax share held by Novack was exchanged for the $15.50 offer price. All outstanding stock options, performance stock units (PSUs) and restricted stock units (RSUs) were cancelled and converted into cash based on the offer price and the number of underlying shares. For equity awards granted in 2025, half of the related cash amount remains subject to vesting and is scheduled to vest six months after the effective time.

Positive

  • None.

Negative

  • None.
Insider Novack David F
Role President & COO
Type Security Shares Price Value
Disposition Stock Option (Right to Buy) 150,000 $0.00 --
Disposition Stock Option (Right to Buy) 150,000 $0.00 --
Disposition Stock Option (Right to Buy) 150,000 $0.00 --
Disposition Stock Option (Right to Buy) 150,000 $0.00 --
Disposition Stock Option (Right to Buy) 95,000 $0.00 --
Disposition Stock Option (Right to Buy) 93,000 $0.00 --
Disposition Restricted Stock Units 22,620 $0.00 --
Disposition Restricted Stock Units 37,576 $0.00 --
U Common Stock 63,334 $0.00 --
Grant/Award Common Stock - Performance Stock Units 67,860 $0.00 --
Disposition Common Stock - Performance Stock Units 67,860 $0.00 --
Grant/Award Common Stock - Performance Stock Units 56,364 $0.00 --
Disposition Common Stock - Performance Stock Units 56,364 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Restricted Stock Units — 0 shares (Direct); Common Stock — 0 shares (Direct); Common Stock - Performance Stock Units — 67,860 shares (Direct)
Footnotes (1)
  1. This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price. Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2026. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027. Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. The stock option was granted to the Reporting Person in 2025. The restricted stock units ("RSUs") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Novack David F

(Last) (First) (Middle)
C/O DYNAVAX TECHNOLOGIES
2100 POWELL STREET, SUITE 720

(Street)
EMERYVILLE CA 94608

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DYNAVAX TECHNOLOGIES CORP [ DVAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & COO
3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/10/2026 U(1)(2) 63,334 D (3) 0 D
Common Stock - Performance Stock Units 02/10/2026 A 67,860 A (4) 67,860 D
Common Stock - Performance Stock Units 02/10/2026 D(1)(2) 67,860 D (5) 0 D
Common Stock - Performance Stock Units 02/10/2026 A 56,364 A (6) 56,364 D
Common Stock - Performance Stock Units 02/10/2026 D(1)(2) 56,364 D (5) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $6.805 02/10/2026 D(1)(2) 150,000 (7) (7) Common Stock 150,000 (7) 0 D
Stock Option (Right to Buy) $9.41 02/10/2026 D(1)(2) 150,000 (7) (7) Common Stock 150,000 (7) 0 D
Stock Option (Right to Buy) $12.74 02/10/2026 D(1)(2) 150,000 (7) (7) Common Stock 150,000 (7) 0 D
Stock Option (Right to Buy) $11.12 02/10/2026 D(1)(2) 150,000 (7) (7) Common Stock 150,000 (7) 0 D
Stock Option (Right to Buy) $12.48 02/10/2026 D(1)(2) 95,000 (7) (7) Common Stock 95,000 (7) 0 D
Stock Option (Right to Buy)(8) $12.69 02/10/2026 D(1)(2) 93,000 (7) (7) Common Stock 93,000 (7) 0 D
Restricted Stock Units (9) 02/10/2026 D(1)(2) 22,620 (10) (10) Common Stock 22,620 (10) 0 D
Restricted Stock Units (11) 02/10/2026 D(1)(2) 37,576 (10) (10) Common Stock 37,576 (10) 0 D
Explanation of Responses:
1. This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
2. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
3. Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price.
4. Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2026.
5. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
6. Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027.
7. Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
8. The stock option was granted to the Reporting Person in 2025.
9. The restricted stock units ("RSUs") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024.
10. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
11. The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025.
David F. Novack, by /s/ Trevor Dutcher, Attorney-in-fact 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Dynavax (DVAX) Form 4 for David F. Novack report?

The Form 4 reports automatic changes to David F. Novack’s Dynavax equity tied to Sanofi’s acquisition. His common shares, options, PSUs and RSUs were cancelled and converted into cash based on the $15.50-per-share offer price at the merger’s effective time.

What were the key terms of Sanofi’s acquisition of Dynavax (DVAX)?

Sanofi, through a wholly owned subsidiary, completed a tender offer to acquire all Dynavax common shares for $15.50 per share in cash. The subsidiary then merged into Dynavax on February 10, 2026, making Dynavax an indirect wholly owned subsidiary of Sanofi.

How were David Novack’s Dynavax stock options treated in the merger?

All outstanding stock options were cancelled at the merger’s effective time and converted into cash. The cash amount equals the number of option shares multiplied by the excess of the $15.50 offer price over the exercise price, with certain 2025 grants partly subject to later vesting.

What happened to David Novack’s Dynavax PSUs under the Sanofi deal?

Each outstanding PSU award was cancelled and converted into cash. The cash equals shares issuable at 150% of target performance times the $15.50 offer price. For PSUs granted in 2025, half of that cash remains subject to vesting six months after the effective time.

How were David Novack’s Dynavax RSUs handled in the merger?

Each outstanding RSU award was cancelled and converted into a cash right. The cash equals the number of RSU shares times the $15.50 offer price. For RSUs granted in 2025, half of the cash is subject to vesting requirements and scheduled to vest six months after the effective time.

Which Dynavax performance periods applied to David Novack’s PSUs in this Form 4?

The filing notes 2024 PSUs with performance measured through December 31, 2026, and 2025 PSUs with performance measured through December 31, 2027. Despite these schedules, all such PSU awards were cancelled and settled for cash at the merger’s effective time.